rexresearch
Urolithin-A Longevity
https://www.sciencedirect.com/science/article/pii/S1568163724002241
Ageing Research Reviews, Volume 100, September 2024, 102406
Targeting aging with urolithin A in humans: A systematic review
Hodzic Kuerec et al
Abstract -- Urolithin A (UA) is a gut metabolite derived from ellagic acid. This systematic review assesses the potential geroprotective effect of UA in humans. In five studies including 250 healthy individuals, UA (10–1000 mg/day) for a duration ranging from 28 days to 4 months, showed a dose-dependent anti-inflammatory effect and upregulated some mitochondrial genes, markers of autophagy, and fatty acid oxidation. It did not affect mitochondrial maximal adenosine triphosphate production, biogenesis, dynamics, or gut microbiota composition. UA increased muscle strength and endurance, however, had no effect on anthropometrics, cardiovascular outcomes, and physical function. Unrelated adverse events were mild or moderate. Further research across more physiological systems and longer intervention periods is required.
https://www.nature.com/articles/s43587-025-00996-x
Nature Aging, 31 October 2025
Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial
Dominic Denk, et al
Abstract -- Mitochondrial dysfunction and stem cell exhaustion contribute to age-related immune decline, yet clinical interventions targeting immune aging are lacking. Recently, we demonstrated that urolithin A (UA), a mitophagy inducer, expands T memory stem cells (TSCM) and naive T cells in mice. In this randomized, double-blind, placebo-controlled trial, 50 healthy middle-aged adults received oral UA (1,000 mg day−1) or placebo for 4 weeks; time points of analysis were baseline and day 28. Primary outcomes were phenotypical changes in peripheral CD3+ T cell subsets and immune metabolic remodeling. UA expanded peripheral naive-like, less terminally exhausted CD8+ cells (treatment difference 0.50 percentage points; 95% CI = 0.16 to 0.83; P = 0.0437) while also increasing CD8+ fatty acid oxidation capacity (treatment difference = 14.72 percentage points; 95% confidence interval (CI) = 6.46 to 22.99; P = 0.0061). Secondary outcomes included changes in plasma cytokine levels (IL-6, TNF, IL-1β, IL-10), immune populations assessed via flow cytometry, immune cell function, and mitochondrial content. Analysis revealed augmented mitochondrial biogenesis in CD8+ cells, increased peripheral CD56dimCD16bright NK cells, and nonclassical CD14loCD16hi monocytes in UA-treated participants, as well as improved activation-elicited TNF secretion in T cells and bacterial uptake by monocytes. Exploratory single-cell RNA sequencing demonstrated UA-driven transcriptional shifts across immune populations, modulating pathways linked to inflammation and metabolism. These findings indicate that short-term UA supplementation modulates human immune cell composition and function, supporting its potential to counteract age-related immune decline and inflammaging. ClinicalTrials.gov registration number: NCT05735886.
https://www.youtube.com/watch?v=XiBLvCGEqAc
Longevity Fact Check: What Urolithin A Really Does to Your Immune System
Mark Hyman, MD and Timeline
This brings Dr. Hyman to one of the most promising compounds for targeting mitochondrial health: Urolithin A. He explains what it is (a natural molecule your gut can make from foods like pomegranates and walnuts) and the problem: only 30-40% of people have the right gut bacteria to produce it naturally.
Dr. Hyman discusses a new clinical trial on Mitopure (a pure, bioavailable form of Urolithin A) that found supplementing with 1000mg led to a "more youthful immune profile". In just four weeks, T-cells became more responsive, markers of inflammation went down, and mitochondrial energy production improved—helping the immune system act younger and more efficiently...
https://www.youtube.com/watch?v=EyVkC5QbOFo
Urolithin A : Youth Cell Secret: Longevity Expert Reveals New Anti-Aging Compound
Dave and Chris break down the full science of urolithin A, the postbiotic compound unlocked from pomegranate by gut bacteria, and why it triggers mitophagy to clear out damaged mitochondria and replace them with high-functioning ones. They cover why only 30 to 40 percent of people can produce urolithin A from food alone, how one month of supplementation measurably improved immune cell populations in people aged 50 to 70, and why Dave has stacked this into his daily longevity protocol alongside NAD precursors and nootropics for years. If you are serious about biohacking your mitochondria, extending healthspan, and doing smarter not harder longevity work, this episode delivers the deep science to back it up.
Patents
COMBINATIONS COMPRISING AN UROLITHIN COMPOUND AND A GINSENG OR NOTOGINSENG DERIVED COMPOUND OR A GINSENG OR NOTOGINSENG EXTRACT -- AU2024367918
The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and one or more ginseng-derived compounds or a ginseng extract; and/or one of more notoginseng-derived compounds or a notoginseng extract. The invention also relates to uses of such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for non-therapeutic uses.
UROLITHIN FOR IMPROVING PERFORMANCE IN ELITE AND SUB-ELITE ATHLETES -- AU2024279527
ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS -- US2025375415
Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
UROLITHIN COMBINATIONS -- US2025367099
Described is a composition comprising: (a) a compound of formula (I), or a salt, prodrug, metabolite or derivative thereof;wherein:A, B, C, D, W, X, Y and Z are each independently selected from H and OH; and(b) one of more agents selected from agents for improving skin health, wherein the agents for improving skin health are selected from one or more of the following: (i) one or more ceramides, for example, one or more phytoceramides;(ii) a carotenoid, for example, lycopene and/or lutein;c. zinc or a salt thereof;d. astaxanthin; and optionallye. L-lysine;f. one or more NAD boosters, for example, nicotinamide and/or co-enzyme Q10;g. eggshell membrane or an extract thereof; and/orh. biotin, or a derivative thereof.
IMMUNE HEALTH IMPROVERS -- US2025345309
Disclosed are compositions that improve the functioning of the immune system in human subjects, in particular human subjects in which the immune system is of reduced effectiveness, or at risk of becoming less effective. Benefits relate in particular to the amelioration of immune aging, in particular, by the administration of urolithins, for example, urolithin A.
NON-THERAPEUTIC USE OF UROLITHIN A FOR IMPROVING COGNITIVE FUNCTION -- WO2012088519
Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
THERAPEUTIC USES OF UROLITHIN DERIVATIVES -- US2024139149
Methods for treating neuromuscular disorders, muscular disorders, heart diseases, pulmonary fibrosis, liver diseases, inflammatory bowel diseases, or cancer are disclosed. A method of enhancing cancer immunotherapy is also disclosed.
UROLITHIN COMPOUNDS FOR ENHANCING OR IMPROVING FERTILITY -- US2025213524
The invention provides a compound of formula (I), or salt thereof, wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; for use in a method of enhancing or improving fertility in a male or female subject, for example, a human male subject. The invention also provides a method of enhancing or improving fertility in a subject (for example a male subject) comprising administering a compound of formula (I) to the subject, and compositions that find use in such methods.
COMPOSITIONS COMPRISING NICOTINAMIDE RIBOSIDE AND A UROLITHIN -- US2022105117
A composition comprising:a) nicotinamide riboside andb) a urolithin which is a compound of formula (I) or a salt thereof:wherein:A, B, C and D are each independently selected from H and OH;W, X and Y are each independently selected from H and OH; andZ is selected from H and OH.The compositions are useful as medicaments, for example for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases and as dietary supplements, functional foods and beverages, and specialised nutrition or medical foods.
Production process of urolithin A -- CN119351487
The invention relates to the technical field of extraction and utilization of chemical substances in walnut green seedcases, in particular to a production process of urolithin A. The production process specifically comprises the following steps: obtaining the walnut green seedcases; walnut green seedcase is mashed into pulp, a stabilizing solution is added, ultrasonic treatment is performed after uniform stirring, the fermentation substrate is obtained, and the stabilizing solution is an aqueous solution of a compound of sulfydryl-beta-cyclodextrin and chitosan; primary fermentation: inoculating a microbial bacterial liquid A for anaerobic fermentation, then filtering and collecting filtrate, the microbial bacterial liquid A being obtained by respectively inoculating bacillus velezensis and bacillus coagulans into a culture medium A for shake cultivation and activation and then mixing the bacillus velezensis and the bacillus coagulans; secondary fermentation: inoculating the filtrate with a microbial bacterial liquid B for anaerobic fermentation again, wherein the microbial bacterial liquid B is obtained by inoculating enterococcus faecium into a culture medium B for culture; and extracting. According to the method, the stabilizing solution is added into the walnut green seedcase, and two-stage fermentation is performed, so that the yield and the conversion rate of urolithin A are remarkably improved, and the method is safe, environmentally friendly and capable of being industrialized.